July 1, 2026 · Form 4 insider transaction
Snellgrove Darren bought 41,554 shares of Halozyme Therapeutics, Inc. at $0.00 per share, a transaction worth N/A. The trade was recorded as grant or award and disclosed on an SEC Form 4, filed 1 day after the transaction.
This award vests one-third on the first anniversary of the grant date and then one-third on each anniversary date thereafter.